Ryman Healthcare Limited logo

DSM Ongoing Disclosure – Cheyne Chalmers

Insider Disclosure31 January 2024RYMHealthcare

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and

Name of listed issuer:

Ryman Healthcare Limited

Date this disclosure made:

30 January 2024

Date of last disclosure:

15/03/2023

Director or senior manager giving disclosure

Full name(s):

Elizabeth Cheyne Chalmers

Name of listed issuer:

Ryman Healthcare Limited

Name of related body corporate (if applicable):

Position held in listed issuer:

Ryman NZ CEO

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:

Ordinary shares (NZX code: RYM)

Nature of the affected relevant interest(s):

Legal and beneficial ownership

For that relevant interest-

Number held in class before acquisition or disposal:

1998

Number held in class after acquisition or disposal:

Legal and beneficial ownership in 1998 ordinary shares and

beneficial ownership in 1713.92624357 ordinary shares

Current registered holder(s):

Registered holder(s) once transfers are registered:

Elizabeth Cheyne Chalmers, Sharesies Nominee Limited

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:

Class of underlying financial products:

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying

financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative(if any):

The price specified in the terms of the derivative (if any):

Any other details needed to understand how the amount of the consideration payable

under the derivative or the value of the derivative is affected by the value of the

underlying financial products:

For that derivative,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the

relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates: One (1)

Details of transactions requiring disclosure-

Date of transaction:29-Jan-24

Nature of transaction:

On Market Purchase

Name of any other party or parties to the transaction (if known):N/A

The consideration, expressed in New Zealand dollars, paid or received for the

acquisition or disposal. If the consideration was not in cash and cannot be readily by

converted into a cash value, describe the consideration:

$9,923.63 (being $5.79 per share)

Number of financial products to which the transaction related: 1713.926244

If the issuer has a financial products trading policy that prohibits directors or senior

managers from trading during any period without written clearance (a closed period)

include the following details—

Whether relevant interests were acquired or disposed of during a closed period:No

Whether prior written clearance was provided to allow the acquisition or disposal to

proceed during the closed period:

Yes

Date of the prior written clearance (if any):

25/01/2024

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:

Nature of relevant interest:

For that relevant interest,-

Number held in class:

Current registered holder(s):

For a derivative relevant interest,-

Type of derivative:

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying

financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable

under the derivative or the value of the derivative is affected by the value of the

underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the

relevant interest in the derivative:

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this

disclosure is correct and that I am duly authorised to make this disclosure by all

persons for whom it is made.

Signature of director or officer:

Date of signature:

31 January 2024

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior

manager of a listed issuer, or of a related body corporate, or in specified derivatives.

The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the

aquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial

Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in

this notice.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.